#healthinequalities #Bloodcancer #Bloodcancerpatients #Bloodcancertreatment #BloodCancerAlliance #bloodcancertreatments #NICEapproval #pharmaceuticalcompanies #NICEappraisals #patientoutcomes #CARTtherapy #CiltaCel #myeloma #NICEappraisalprocesses #patientaccess
pharmatimes.com/news/blood-c...
pharmatimes.com/news/blood-c...
Blood cancer patients face treatment access disparity - PharmaTimes
New research highlights NHS approval gap compared to other cancers
pharmatimes.com
March 6, 2025 at 10:23 AM
This week's IL newsletter: Treatment for Duchenne MD – Long-awaited approval means a new #NHSTreatment is now available for eligible children with Duchenne muscular dystrophy. #DuchenneMuscularDystrophy #RareDisease #NICEApproval #Givinostat #HealthAndCare #ILnews
buff.ly/outYncK
buff.ly/outYncK
May 28, 2026 at 12:01 PM
This week's IL newsletter: Treatment for Duchenne MD – Long-awaited approval means a new #NHSTreatment is now available for eligible children with Duchenne muscular dystrophy. #DuchenneMuscularDystrophy #RareDisease #NICEApproval #Givinostat #HealthAndCare #ILnews
buff.ly/outYncK
buff.ly/outYncK
This week's IL newsletter: Myasthenia Gravis treatment – A new #NHSTreatment offers fresh hope following approval for a targeted therapy. #MyastheniaGravis #RareDisease #NICEApproval #HealthAndCare #ILnews
buff.ly/u41H1NT
buff.ly/u41H1NT
May 7, 2026 at 8:00 AM
This week's IL newsletter: Myasthenia Gravis treatment – A new #NHSTreatment offers fresh hope following approval for a targeted therapy. #MyastheniaGravis #RareDisease #NICEApproval #HealthAndCare #ILnews
buff.ly/u41H1NT
buff.ly/u41H1NT
#oncology #NICE #AstraZeneca #dualimmunotherapy #advancedlivercancer #livercancer #Imfinzi #durvalumab #Imjudo #tremelimumab #Advancedhepatocellularcarcinoma #unresectablehepatocellularcarcinoma #HCC #NICEapproval #STRIDEregimen #primarylivercancer #BritishLiverTrust
zurl.co/M3ftp
zurl.co/M3ftp
NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer - PharmaTimes
Imfinzi and Imjudo combination recommended as first-line treatment
pharmatimes.com
September 9, 2025 at 8:18 AM
Feed: "Pharmacy Business"
By: Lakshmi Prabha on Saturday, May 9, 2026
By: Lakshmi Prabha on Saturday, May 9, 2026
Hope for Duchenne muscular dystrophy patients as NICE approves givinostat
Exciting news for children with Duchenne muscular dystrophy as NICE recommends Duvyzat for NHS use! Will this new treatment help them lead more independent lives for longer? More long-term evidence is needed, but the potential is promising. Let's support these young warriors in their fight against DMD! #HopeForDMD #NICEapproval #Duvyzat
www.pharmacy.biz
May 10, 2026 at 10:54 AM
Feed: "Pharmacy Business"
By: Lakshmi Prabha on Saturday, May 9, 2026
By: Lakshmi Prabha on Saturday, May 9, 2026